February 22, 2013

CURRICULUM VITAE

Name: Robert Turner Schooley

Address: 6603 Mower Place, San Diego, CA 92130

Date of Birth: November 10, 1949

Place of Birth: Washington, D.C.

Education:

1970 B.S. Washington and Lee University, Lexington, VA1974 M.D. The Johns Hopkins University School of Medicine, Baltimore, MD

Postdoctoral Training:

Internship and Residencies:

1974-1975 Intern in Medicine, The Johns Hopkins Hospital, Baltimore, MD1975-1976 Assistant Resident in Medicine, The Johns Hopkins Hospital, Baltimore, MD

Research Fellowships:

1976-1977 Clinical Associate, Laboratory of Clinical Investigation,National Institute of Allergy and Infectious Diseases,National Institutes of Health, Bethesda, MD

1977-1978 Chief Clinical Associate, Laboratory of ClinicalInvestigation, National Institute of Allergy and Infectious Diseases,National Institutes of Health, Bethesda, MD

1978-1979 Medical Officer, Medical Virology Section, Laboratory of Clinical Investigation, National Institute of Allergy andInfectious Diseases, National Institutes of Health, Bethesda, MD

1979-1981 Clinical and Research Fellow, Infectious Disease Unit,Massachusetts General Hospital, Boston, MA

1979-1981 Research Fellow in Medicine, Harvard Medical School, Boston, MA

Licensure and Certification:

1974-1981 Maryland State Board of Medical Examiners1977 Diplomat, American Board of Internal Medicine1979-1991 Massachusetts State Board of Medical Examiners1981-1982 New York State Board of Medical Licensure1990- Colorado State Board of Medical Examiners2005- Medical Board of California

1

Academic Appointments:

1981-1983 Instructor in Medicine, Harvard Medical School, Boston, MA1983-1987 Assistant Professor of Medicine, Harvard Medical School, Boston, MA1987-1990 Associate Professor of Medicine, Harvard Medical School, Boston, MA1990-2004 Professor of Medicine, Head, Division of Infectious Diseases, University of

Colorado Health Sciences Center, Denver, CO.1994-2004 Tim Gill Professor of Medicine, University of Colorado Health Sciences

Center, Denver, CO.2002-2004 Director, Colorado Center for AIDS Research2005- Professor of Medicine and Head, Division of Infectious Diseases, University

of California, San Diego.2007 - Academic Vice Chair, Department of Medicine, University of California,

San Diego

Hospital Appointments:

1981-1982 Clinical Assistant in Medicine, Massachusetts General Hospital, Boston, MA1983-1986 Assistant in Medicine, Massachusetts General Hospital, Boston, MA1987-1989 Assistant Physician, Massachusetts General Hospital, Boston, MA1990 Associate Physician, Massachusetts General Hospital, Boston, MA1990-2006 Physician, University Hospital, Denver, CO1990- 2006 Staff Physician, Denver Veterans Affairs Medical Center, Denver, CO1990-2004 Consultant, Denver Health & Hospitals, Denver, CO2005- Staff Physician, UCSD Healthcare

Other Professional Positions:

1980-1985 Consultant in Internal Medicine, Massachusetts Eye and Ear Infirmary, Boston, MA

1982-1990 Consultant in Infectious Diseases, Harvard University Health Services,Cambridge, MA

Awards and Honors:

1970- Omicron Delta Kappa 1980-3 New Investigator Award, NIAID, NIH1990- American Society for Clinical Investigation1995-present Association of American Physicians1991 John Enders Memorial Lectureship, Infectious Disease Society of America1993-present Who’s Who in the West1993-present Who’s Who in Healthcare and Technology1992-present Best Doctors in America1997-present America’s Top Doctors1999 Bonfils-Stanton Foundation Award for Science or Medicine1999-present Who’s Who in America

2

1999 Honorary Professor, Peking Union Medical College, Beijing, China2007 Chief Residents’ Clinical Teaching Award, University of California, San

Diego2009 Gold Doc Award, Arnold P. Gold Foundation

Major Committee Assignments:

National and International:

1985-1990 Consultant, AIDS Study Sections, National Institutes of Health1990-1992 Chairman, AIDS and Related Retrovirus A (Immunology and Pathogenesis)

Study Section, Division of Research Grants, National Institutes of Health1992-1994 Member, AIDS and Related Retrovirus A (Immunology and Pathogenesis)

Study Section, Division of Research Grants, National Institutes of Health1989-1992 Member, Infectious Disease Merit Review Study Section, Department of

Veterans Affairs1989-1992 Chairman, Immune Based Therapy Working Group, AIDS Clinical Trials

Group, NIAID, NIH1990-1994 Core Immunology Committee, AIDS Clinical Trials Group, NIAID, NIH1990- Scientific Advisory Committee, American Foundation for AIDS Research

(AMFAR)1992-1996 Medical and Scientific Advisory Council, National Hemophilia Foundation1993-1995 Chairman, Core Immunology Committee, AIDS Clinical Trials

Group, NIAID, NIH1991-1995 AIDS Clinical Drug Development Committee (ACDDC), NIAID, NIH1991-1994 Member, Governor's AIDS Council, State of Colorado1992-1995 Member, Program Committee, Interscience Conference of Antimicrobial

Agents and Chemotherapy1992-1996 Chair, Program Committee, US Conference on Human Retroviruses and

Related Infections, American Society for Microbiology1996- Member, Program Committee, US Conference on Human Retroviruses and

Related Infections, Foundation for Human Retroviruses1994-1996 Member, National Task Force for AIDS Drug Development, Department of

Health and Human Services1994-1997 Councilor, American Society for Clinical Investigation1994- Member, Executive Committee, AIDS Clinical Trials Group, NIAID, NIH1995-2000 Chair, AIDS Panel, US-Japan Cooperative Medical Sciences Program, NIH 1995-2002 Chair, Executive Committee, AIDS Clinical Trials Group, NIAID, NIH1995-1996 Member, Office of AIDS Research Advisory Counsel, Department of Health

and Human Services1995-1999 Member, Scientific Program Committee, Infectious Diseases Society of

America1996- Member, External Advisory Committee, Case Western Reserve Center for

AIDS Research1996-1999 Member, Fellowship and Young Investigator Awards Committee, Infectious

Diseases Society of America1997- 2003 Member, AIDS and Cancer Specimen Resource, National Cancer Institute

3

1997 Chair, Scientific Program Committee, Infectious Diseases Society of America

1999-2005 Member, Governing Council, International AIDS Society2000-2003 Chair, Fellowship and Young Investigator Awards Committee, Infectious

Diseases Society of America2002-2008 Member, Hepatitis Research Agenda Committee, AIDS Clinical Trials

Group, NIAID, NIH2002-2004 Director, Colorado Center for AIDS Research2003- Coordinator for International Programs, AIDS Clinical Trials Group, NIAID,

NIH2004-2005 Institute of Medicine Panel on Therapeutics in Resource Limited Settings2004-2006 NIH Vaccine Research Center, Board of Scientific Counselors, NIH2008 Co-Director, American Association for the Study of Liver Diseases Single

Topic Conference, (Viral Hepatitis Therapy: Lessons to Be Learned from HIV)

2009- Member, Scientific Advisory Committee, University of Hong Kong AIDS Research Center

2010-2011 Member, Drug Development and Resistance (DDR) Study Section, Division of Extramural Activities, National Institutes of Health

2010 Member, Reference Group on Medical Education, World Health Organization

2010- Member, Scientific Advisory Board, President’s Emergency Program for AIDS Relief (PEPFAR), United States Department of State

2011-2013 Chair, Drug Development and Resistance (DDR) Study Section, Division of Extramural Activities, National Institutes of Health

Medical School/Health Sciences Center:

1985-1988 Curriculum Design Committee, Identity and Defense, Oliver Wendell Holmes Pathway, Harvard Medical School

1990-1991 Committee on Research Safety, University of Colorado Health Sciences Center

1996-2002 Member, Faculty Senate, UCHSC School of Medicine2000-2001 President, Faculty Senate, UCHSC School of Medicine2000-2004 Member, Faculty Assembly, UCHSC2002-2004 Member, Internship Selection Committee, Department of Medicine, UCHSC

School of Medicine2006-2009 Institutional Biosafety Committee, UCSD2007- Member, Finance Committee, UCSD School of Medicine2008- Member, Space Committee, Department of Medicine, UCSD2009- Member, Steering Committee, UCSD Global Health Initiative2009-2010 Chair, Institutional Biosafety Committee, UCSD

Hospital:

1984-1986 Subcommittee on Research Safety, Committee on Research, Massachusetts General Hospital

4

1986-1988 Internship Selection Committee, Medical Services, Massachusetts General Hospital

1986-1989 Subcommittee on Human Studies, Committee on Research, Massachusetts General Hospital

2000-2002 Member, Medical Board, University of Colorado Hospital2005-2008 Member, Infection Control Committee, UCSD Medical Center2005-2006 Peer Review Coordinator for Infectious Diseases, UCSD Medical Center

Professional Societies:

1980-1985 American College of Physicians1982-1996 American Association of Immunologists1983- American Association for the Advancement of Science1984- Fellow, Infectious Disease Society of America1990- American Society for Clinical Investigation1990- American Society for Microbiology1992-2008 Clinical Immunology Society1995- Association of American Physicians2007- American Society of Tropical Medicine and Hygiene2008- Fellow, Royal Society of Medicine, UK

Major Research Interests:

1. Viral Pathogenesis and therapy2. Lymphocyte Activation and Regulation3. Acquired Immune Deficiency Syndrome4. International Medicine

Teaching Experience:

1980-1990 Lecturer, 4th Year Microbiology Course, Harvard Medical School1981-1990 Attending Physician, Medical Service, Massachusetts General Hospital1981-1990 Grand Rounds, Massachusetts General Hospital (Pediatrics, Medicine,

Dermatology, Surgery, Neurology, Pulmonary, Arthritis)1982-1990 Lecturer, Postgraduate Courses, Massachusetts General Hospital Harvard

Medical School (Pediatrics, Neurology, Surgery, Primary Care, Rheumatology, Internal Medicine, Infectious Disease, Surgical Oncology, immunology, Anesthesia, Pediatric Anesthesia)

1982-1990 Supervisor, Postdoctoral Fellows in Virology1984-1990 Lecturer, Microbiology-Pathophysiology Course 701, Harvard Medical

School1984-1992 Lecturer, Infectious Disease, Arthritis Postgraduate Course, Brigham and

Women's Hospital Harvard Medical School1985-1987 Course Development, Curriculum Design Committee, Identity and Defense,

Oliver Wendell Holmes Pathway, Harvard Medical School1985-1990 Director, Fellowship Program, Infectious Disease Unit, Massachusetts

General Hospital

5

1990-2004 Medical Grand Rounds, University of Colorado Health Sciences Center1990-2003 Lecturer, Postgraduate Medical Education Courses, University of Colorado

Health Sciences Center1990-2004 Section Leader, Pathophysiology of Infectious Diseases (Microbiology

6000), University of Colorado Health Sciences Center1997-2003 Lecturer, Pharmacology 60002002-2004 Course Director, Pathophysiology of Infectious Diseases (Microbiology

6000), University of Colorado Health Sciences Center2002 Lecturer, Microbiology 6000, University of Colorado Health Sciences

Center2003 Lecturer, Virology Graduate Course, University of Colorado Health Sciences

Center2005- Lecturer, SOM 208, Principles of Human Disease

Principal Clinical and Hospital Service Responsibilities:

1981-1990 Attending Physician, Medical Service, Massachusetts General Hospital1982-1990 Consultant in Infectious Diseases, Transplant Program, Massachusetts

General Hospital1990-2006 Physician, University of Colorado Hospital, Denver, CO1990-2006 Staff Physician, Denver Veterans Affairs Medical Center, Denver, CO1991-2004 Staff Physician, Denver Health & Hospital, Denver, CO2005- Staff Physician, UCSD Medical Center

Major Administrative Responsibilities:

1985-1990 Director, Postdoctoral Fellowship Training Program, Infectious Disease Unit, Massachusetts General Hospital

1989-1990 Acting Co-Director, Clinical Center, Harvard AIDS Institute1990-2004 Director, Infectious Disease Division, University of Colorado Health

Sciences Center2002-2004 Director, Colorado Center for AIDS Research2005- Director, Division of Infectious Diseases, University of California, San

Diego2005-2006 Director, Postdoctoral Fellowship Training Program, University of

California, San Diego2005- Co-Director, International Program, Center for AIDS Research, University

of California, San Diego2012- Associate Director, Center for AIDS Research, University of California, San

Diego

Editorial Boards:

1996- 2001 Antimicrobial Agents and Chemotherapy1987-1998 Biotherapy1987- Journal of Acquired Immune Deficiency Syndromes1992-1999 Clinical and Diagnostic Laboratory Immunology

6

1994- AIDS2002- Section Editor, Clinical Infectious Diseases (HIV/AIDS)

Student Instructional Activities

Postdoctoral Fellows

Year Name Current Position

1980-2 Joseph B. Garner, M.D. Associate Professor of MedicineUniversity of Connecticut School of Medicine

1982-4 Richard Blumberg, M.D. Professor of MedicineHarvard Medical School

1984-7 Bruce D. Walker, M.D. Professor of MedicineHarvard Medical School

1987-8 Laura Fisher, M.D. Associate Professor of MedicineCornell University School of Medicine

1986-90 Tyler Curiel, M.D. Professor of MedicineDirector, San Antonio Cancer InstituteAssociate DeanUniversity of Texas, San Antonio

1987-90 Daniel R. Kuritzkes, M.D. Professor of MedicineHarvard Medical School

1990-3 Elizabeth McFarland, M.D. Associate Professor of Pediatrics(with Daniel Kuritzkes) University of Colorado Health Sciences Center

2002-4 David L. Wyles, M.D. Assistant Professor of Medicine(with Constance A. Benson) University of California, San Diego

UCSD Mentoring and Supervision

Postdoctoral Fellows

2005- 2008 Sanjay Mehta, M.D.Immunopathogenesis of Leishmania Infection

Robert C. Huang, M.D.2006- 2007 Development of a Green Fluorescent Protein Transfected Leishmania-based

model for the study of Leishmanial infection

Julio Gutierrez, M.D., Ph.D.

7

2009- Pathogenesis and treatment of HCV infection

Cathy Logan, M.D.2010 Rapid Point-of-Care Diagnostics for Resource Limited Settings

UCSD Medical Students

2006 Carly GuthrieMalarial parasite burden in HIV-1 co-infected patients in Manaus, Brazil

2006 Jacob DurantDevelopment of a Multiplexed Antigen and Antibody Detection System for the Diagnosis of Infectious Diseases

2007 Marika OrlovEpidemiology and medical impact of P. falciparum and T. solium in Mozambique

Pre-doctoral Students UCSD Graduate School

2006 Leslie Crews, Ph.D. CandidateMinor Proposition Thesis Committee MemberRole of B Lymphocyte Receptors in the Extrahepatic Signaling Effects of Hepatitis C Virus

2006 Nisha Maranthe, Ph.D. CandidateMinor Proposition Thesis Committee MemberThe role of NS4B in the replication of Hepatitis C virus

2007 Morgan A. Pence, Ph. D. CandidateMinor Proposition Thesis Committee MemberInhibition of Granzyme-mediated Apoptosis in Hepatitis C Infection

Ph.D Sponsor

2008- Marika OrlovPathogenesis and Clinical Implications of the Interactions Between HIV-1 and P. falciparum

8

Bibliography

I. Original Articles

1. Kimberg DV, Field M, Gershon E, Schooley RT and Henderson A. Effects of cycloheximide on the response of intestinal mucosa to cholera enterotoxin. J Clin Invest. 1973; 52:1376-83.

2. Schooley RT, Wagley PF and Lietrnan PS. Edema associated with ibuprofen therapy. JAMA. 1977; 237:1716-7.

3. Lightman NI and Schooley RT. Adult-onset acid maltase deficiency. Case report of an adult with severe respiratory difficulty. Chest. 1977; 72:250-2.

4. Haynes BF, Schooley RT, Grouse JE, Payling-Wright CR, Dolin R and Fauci AS.Characterization of thymus-derived lymphocyte subsets in acute Epstein-Barr virus-induced infectious mononucleosis. J Immunol. 1979; 122:699-702.

5. Haynes BF, Schooley RT, Payling-Wright CR, Grouse J, Dolin R and Fauci AS. Emergence of suppressor cells of immunoglobulin synthesis during acute Epstein-Barr virus-induced infectious mononucleosis. J Immunol. 1979; 123:2095-101.

6. Schooley RT, Haynes BF, Payling-Wright CR, Grouse J, Dolin R and Fauci AS. Mechanism of Epstein-Barr virus-induced human B-lymphocyte activation. Cellular Immunol. 1980; 56:518-25.

7. Cupps TR, Cotton DJ, Schooley RT and Fauci AS. Facial erysipelas in the immunocompromised host. Report of two cases. Arch Dermatol. 1981; 117:47-9.

8. Wasson DL, Loegering DA, Solley GO, Moore SB, Schooley RT, Fauci AS and Gleich GJ. Elevated serum levels of the eosinophil granule major basic protein in patients with eosinophilia. J Clin lnvest. 1981; 67:651-61.

9. Flaum MA, Schooley RT, Fauci AS and Gralnick HR. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. I. Hematologic manifestations. Blood. 1981; 58:1012-20.

10. Schooley RT, Flaum MA, Gralnick HR and Fauci AS. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations. Blood. 1981; 58:1021-6.

11. Schooley RT, Haynes BF, Grouse J, Payling-Wright CR, Fauci AS and Dolin R. Development of suppressor T-lymphocytes for Epstein-Barr virus-induced B-lymphocyte outgrowth during acute infectious mononucleosis: Assessment by two quantitative systems. Blood. 1981; 57:510-7.

9

12. Rubin RH, Carney WP, Schooley RT, Colvin RB, Burton RC, Hoffman RA, Hansen WP, Cosimi AB, Russell PS and Hirsch MS. The effect of infection of T-lymphocyte subpopulations: a preliminary report. Int J lmmunopharmacol. 1981; 3:307-12.

13. Dolin R, Reichman RC, Roessner KD, Tralka TS, Schooley RT, Gary W and Morens D.Detection by immune electron microscopy of Snow Mountain agent of acute viral gastroenteritis. J Inf Dis. 1982; 146:184-9.

14. Thorley-Lawson DA, Schooley RT, Bhan AK and Nadler LM. Epstein-Barr virus superinduces a new human B cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts. Cell. 1982; 30:415-25.

15. Geraci JR, St. Austin DJ, Barker, IK, Webster RG, Hinshaw VS, Bean WJ, Ruhnke HL, Prescott JH, Early G, Baker AS, Madoff S and Schooley RT. Mass mortality of harbor seals: pneumonia associated with influenza A virus. Science. 1982; 215:1129-31.

16. Thorley-Lawson DA, Geilinger K and Schooley RT. Monoclonal antibody against EBV-associated transformation antigen detected in vitro and in vivo. Protides Biol Fluid Colloq. 1982; 29:739-42.

17. Quinnan GV, Schooley RT, Dolin R, Ennis FA, Gross P and Gwaltney JM. Serological responses and systemic reactions in adults with monovalent A/USSR/77 and trivalent A/USSR/77-A/Texas/77-B/Hong Kong/72 influenza vaccine. Rev Infect Dis. 1983; 5:748-57.

18. Gottdiener JS, Maron BJ, Schooley RT, Harley JB, Roberts WC and Fauci AS. Two-dimensional echocardiographic assessment of the idiopathic hyper-eosinophilic syndrome. Anatomic basis of rnitral regurgitation and peripheral embolization. Circulation. 1983; 67:572-8.

19. Slovin SF, Schooley RT and Thorley-Lawson DA. Analysis of cellular immune response to EBV by using cloned T cell lines. J Immunol. 1983; 130:2127-32.

20. Schooley RT, Hirsch MS, Colvin R.B, Cosimi AB, Tolkoff-Rubin NE, McCluskey RT, Burton RC, Russell PS, Herrin JT, Delmonico FL, Giorgi JV, Henle W and Rubin RH. Association of herpes virus infections with T-lymphocyte subset alterations, glomerulopathy, and opportunistic infections following renal transplantation. N Engl J Med. 1983; 308:307-13.

21. Schooley RT, Byington R and Falk Jr. LA. Phenotypic analysis of New World primate mononuclear cell surface antigens. J Med Primatology. 1983; 12:30-40.

22. Hirsch MS, Schooley RT, Cosimi AB, Russell PS, Delmonico FL, Tolkoff-Rubin NE, Herrin JT, Cantell K, Farrell ML, Rota TR and Rubin RH. Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal transplant recipients. N Engl J Med. 1983; 308:1489-93.

10

23. Delmonico FL, Cosimi AB, Jaffers GJ, Schooley RT, Rubin RH, Tolkoff-Rubin N, Fang LT and Russell PS. Immunological monitoring of diabetic and nondiabetic recipients of renal allografts. J Surg Research. 1983; 35:271-6.

24. Hochberg FH, Miller G, Schooley RT, Hirsch MS, Fiorino P and Henle W. Central-nervous-system lymphoma related to Epstein-Barr virus. N Engl J Med. 1983; 309:745-8.

25. Falk Jr. LA, Silva D, Byington R and Schooley RT. Long-term propagation of New World primate T-lymphocytes in vitro. Proceedings of the Fifteenth International Leukocyte Culture Conference. Intercell Communicat in Leucocyte Function. 1983; 577-80.

26. Blazar BA, Strome M and Schooley RT. Interferon and natural killing of human lymphoma lines following induction of the Epstein-Barr virus cycle of superinfection. J Immunol. 1984; 132:816-20.

27. Schooley RT, Densen P, Harmon D, Felsenstein D, Hirsch MS, Henle H and Weitzman S. Antineutrophil antibodies in infectious mononucleosis. Am J Med. 1984; 76:85-90.

28. Garner JG, Colvin RB and Schooley RT. A flow cytometric technique for quantitation of B-cell activation. J Immunol Methods. 1984; 67:37-51.

29. Garner JG, Hirsch MS and Schooley RT. Prevention of Epstein-Barr virus-induced B-cell outgrowth by interferon alpha. Infect & Immuno. 1984; 43:920-4.

30. Schooley RT, Arbit DI, Henle W and Hirsch MS. T-Lymphocyte Subset Interactions in the Cell-Mediated Immune Response to Epstein-Barr Virus. Cellular Immun. 1984; 86:402-12.

31. Kelly AP, Schooley RT, Rubin RH and Hirsch MS. Effect of interferon alpha on natural killer cell cytotoxicity in kidney transplant recipients. Clin Immuno & Immunopatho. 1984; 32:20-8.

32. Ho DD, Schooley RT, Rota TR, Kaplan JS, Flynn T, Salahuddin SZ, Gonda MA and Hirsch MS. HTLV-III in the semen and blood of a healthy homosexual man. Science. 1984; 226:451-3.

33. Lind SE, Gross PL, Andiman WA, Stone GC, Schooley RT and Harris NL. Malignant Lymphoma Presenting as Kaposi's Sarcoma in a Homosexual Man with the Acquired Immunodeficiency Syndrome. Ann Intern Med. 1985; 102:338-40.

34. Miller G, Grogan E, Fischer DK, Niederman JC, Schooley RT, Henle W, Lenoir G and Liu CR. Antibody responses to two Epstein-Barr virus nuclear antigens defined by gene transfer. N Engl J Med. 1985; 312:750-5.

35. Thorley-Lawson DA, Nadler LM, Bhan AK and Schooley RT. BLAST-2 (EBVCS), an early cell surface marker of human B cell activation, is superinduced by Epstein-Barr virus. J Immunol. 1985; 134:3007-12.

11

36. Edson CM, Hosler BA, Poodry CA, Schooley RT, Waters DJ and Thorley-Lawson DA. Varicella-zoster virus envelope glycoproteins: biochemical characterization and identification in clinical material. Virol. 1985; 145:62-71.

37. Ho DD, Rota TR, Schooley RT, Kaplan JC, Allen JD, Groopman JE, Resnick L, Felsenstein D, Andrews CA and Hirsch MS. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to Acquired Immunodeficiency Syndrome. N Engl J Med. 1985; 313:1493-7.

38. Hirsch MS, Wormser G, Schooley RT, Ho DD, Felsenstein D, Hopkins CC, Joline C, Duncanson F, Sargadharan MG, Saxinger C and Gallo RC. Risk of nosocomial infection with human T-lymphotropic virus-III (HTLV-III). N Engl J Med. 1985; 312:1-4.

39. Ho DD, Hartshorn KL, Rota TR, Andrews CA, Kaplan JC, Schooley RT and Hirsch MS. Recombinant human interferon alpha-A suppresses HTLV-III replication in vitro. Lancet. 1985; 1:602-4.

40. Sandstrom EG, Schooley RT, Ho DD, Byington R, Sarngadharan MG, MacLane ME, Essex M, Gallo RC and Hirsch MS. Detection of human anti-HTLV-III antibodies by indirectimmunofluorescence using fixed cells. Transfusion. 1985; 25:308-12.

41. Felsenstein D, D'Amico DJ, Hirsch MS, Neumeyer DA, Cederberg DM, de Miranda P and Schooley RT. Treatment of cytomegalovirus retinitis with 9-[2-Hydroxy-1-(Hydroxymethyl)ethoxymethyl] guanine (BWB759U). Ann Intern Med. 1985; 103:377-80.

42. Ho DD, Byington RE, Schooley RT, Flynn T, Rota TR and Hirsch MS. Infrequency of isolation of HTLV-III virus from saliva in AIDS [letter]. N Engl J Med. 1985; 313:1606.

43. Schooley RT, Carey RW, Miller G, Henle W, Eastman R, Mark EJ, Kenyon K, Wheeler EO and Rubin RH. Chronic Epstein-Barr virus infection associated with fever and interstitial pneumonitis. Clinical and serologic features and response to antiviral chemotherapy. Ann Intern Med. 1986; 104:636-43.

44. Blumberg RS, Sandstrom EG, Paradis TJ, Neumeyer DN, Sarngdharan MG, Hartshorn KL, Byington RE, Hirsch MS and Schooley RT. Detection of HTLV-III related antigens and anti-human anti-HTLV-III antibodies by anticomplementary immunofluorescence. J Clin Micro. 1986; 23:1072-7.

45. Whitley RJ, Alford CA, Hirsch MS, Schooley RT, Luby JP, Aoki FY, Hanley D, Nahmias AJ and Soong SJ. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med. 1986; 314:144-9.

46. Vogt MW, Witt DJ, Craven DE, Byington R, Crawford DF, Schooley RT and Hirsch MS.Isolation of HTLV-III/LAV from cervical secretions of women at risk for AIDS. Lancet. 1986; 1:525-7.

12

47. Vogt MW, Ho DD, Bakar SR, Gilbard JP, Schooley RT and Hirsch MS. Safe disinfection of contact lenses after contamination with HTLV-III. Ophthalmol. 1986; 93:771-4.

48. Hartshorn KL, Sandstrom EG, Neumeyer D, Paradis TJ, Chou TC, Schooley RT and Hirsch MS. Synergistic inhibition of HTLV-III replication in vitro by phosphonoformate and recombinant alpha-A interferon. Antimicrob Ag Chemoth. 1986; 30:189-9 1.

49. Sandstrom EG, Andrews CA, Schooley RT, Byington R and Hirsch MS. Suppression of concanavalin A-induced blastogenesis by HTLV-III-infected H9 cells. Clin Immuno & Immunopath. 1986; 40:253-8.

50. D'Amico DJ, Talamo JH, Felsenstein D, Hirsch MS, Albert DM and Schooley RT. Ophthalmoscopic and histologic findings cytomegalovirus retinitis treated with BW-B759U. Arch Ophthalmol. 1986; 104:1788-93.

51. Ho DD, Sarngadharan MG, Hirsch MS, Schooley RT, Rota TR, Kennedy RC, Chanh TC and Sato VL. HIV neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virology. 1987; 61:2024-8.

52. Hartshorn KL, Vogt MW, Chou TC, Blumberg RS, Byington R, Schooley RT and Hirsch MS. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha-A interferon. Antimicro Ag Chemoth. 1987; 31:168-72.

53. Vogt MW, Hartshorn KL, Furman PA, Chou TC, Fyfe JA, Coleman LA, Crumpacker C,Schooley RT and Hirsch MS. Ribavirin antagonizes the effect of azidothymidine (AZT) on HIV replication. Science. 1987; 235:1376-9.

54. Vogt MW, Witt DJ, Craven DE, Byington R, Crawford DF, Hutchison MS, Schooley RT and Hirsch MS. Isolation Patterns of the Human Immunodeficiency Virus (HIV) from cervical secretions during the menstrual cycle of women at risk for AIDS. Ann Intern Med. 1987;106:380-2.

55. Miller G, Grogan E, Rowe D, Rooney C, Heston L, Eastman R, Andiman W, Niederman J, Lenoir G, Henle W, Sullivan J, Schooley R, Vossen J, Straus S and Issekutz T. Selective lack of antibody to a component of EB Nuclear Antigen in patients with chronic active Epstein-Barr virus infection. J Infect Dis. 1987; 156:26-35.

56. Walker BD, Chakrabarti S, Moss B, Paradis TJ, Flynn T, Durno AG, Blumberg RS, Kaplan JC, Hirsch MS and Schooley RT. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature. 1987; 328:345-8.

57. Fischl MA, Richman DD, Grieco M, Gottlieb MS, Volberding P, Laskin D, Leedom JM, Schooley RT, Groopman J, Mildvan D, Jackson GG, Durack D, King D and the AZT Collaborative Working Group. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind placebo-controlled trial. N Engl J Med. 1987; 317:185-91.

13

58. Richman DD and the AZT Collaborative Working Group. The toxicity of 3'-azido-'deoxythymidine (azidothymidine) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med. 1987; 317:192-7.

59. Blumberg RS, Paradis T, Byington R, Henle W, Hirsch MS and Schooley RT. Effects of HIV on the cellular immune response to Epstein-Barr virus in homosexual men: characterization of the cytotoxic response and lymphokine production. J Infect Dis. 1987; 155:877-90.

60. Hartshorn KL, Neumeyer D, Vogt MW, Schooley RT and Hirsch MS. Activity of interferons alpha, beta, and gamma against human immunodeficiency virus replication in vitro. AIDS Res Hum Retroviruses. 1987; 3:125-33.

61. Blumberg RS, Hartshorn KL, Ardman B, Kaplan JC, Paradis TJ, Vogt M, Hirsch MS and Schooley RT. Dot immunobinding assay for detection of human immunodeficiency virus (HIV) associated antigens. J Clin Micro. 1987; 25:1989-92.

62. Whitley RJ, Alford CA, Hirsch MS, Schooley RT, Luby JP, Aoki FY, Hanley D, Nahmias AJ and Soong SJ. Factors indicative of outcome in a comparative trial of acyclovir and vidarabine for biopsy-proven herpes simplex encephalitis. Infection. 1987; 15 Suppl 1:S3-8.

63. Blumberg RS, Paradis TJ, Crawford D, Byington RE, Hirsch MS and Schooley RT. Effects of human immunodeficiency virus on the cytotoxic response to Epstein-Barr Virus (EBV)transformed B-lymphocytes. AIDS Res and Hum Retro. 1987; 3:303-15.

64. Wong KW, D'Amico DJ, Hedges TR 3rd, Soong HK, Schooley RT and Kenyon KR. Ocular involvement associated with chronic Epstein-Barr virus disease. Arch Ophthalmol. 1987; 105:788-92.

65. Blumberg RS, Paradis TJ, Hartshorn KL, Vogt M, Ho DD, Hirsch MS, Leban J, Sato VL and Schooley RT. Antibody-dependent cell-mediated cytotoxicity (ADCC) against cells infected with the Human Immunodeficiency Virus. J Infect Dis. 1987; 156:878-84.

66. Kaplan JC, Crawford DC, Durno AG and Schooley RT. Inactivation of Human Immunodeficiency Virus (HIV) by Betadine. Infect Control. 1987; 8:412-4.

67. Gibas A, Dienstag JL, Schafer AI, Delmonico F, Bynum TE, Schooley RT, Rubin RH and Cosimi AB. The Cure of Hemophilia A by Orthotopic Liver Gastroenterology. 1988; 95:192-4.

68. Tuazon TV, Schneeberger EE, Bhan AK, McCluskey RT, Cosimi AB, Schooley RT, Rubin RH and Colvin RB. Mononuclear cells in acute allograft glomerulopathy. Am J Path. 1987; 129:119-32.

69. Pomerantz RJ, Kuritzkes DR, de la Monte SM, Rota TR, Baker AS, Albert D, Bor DH, Feldman EL, Schooley RT and Hirsch MS. Infection of the Retina by Human Immunodeficiency Virus Type I (HIV-1). N Engl J Med. 1987; 317:1643-7.

14

70. de la Monte SM, Ho DD, Schooley RT, Hirsch MS and Richardson EP Jr. Subacute encephalomyelitis of AIDS and its relation to HTLV-III infection. Neurology. 1987; 37:562-9.

71. Fisher RA, Bertonis JM, Meier W, Johnson VA, Costopoulos DS, Liu T, Tizard R, Walker BD, Hirsch MS, Schooley RT and Flavell RA. HIV infection is blocked in vitro by recombinant soluble T4. Nature. 1988; 331:76-8.

72. Holmes GP, Kaplan JE, Gantz NM, Komaroff AL, Schonberger LB, Straus SE, Jones JE, DuBois RE, Cunningham-Rundles C, Pahwa S, Tosato G, Zegans LS, Purtilo DT, Brown N, Schooley RT and Brus I. Chronic Fatigue Syndrome: A working case definition. Annals Intern Med. 1988; 108:387-9.

73. Fischl MA, Richman DD, Causey DM, Grieco MH, Bryson Y, Mildvan D, Laskin OL, Groopman JE, Volberding PA, Schooley RT, et. al. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. JAMA. 1989; 262:2405-10.

74. Chernow B, Schooley RT, Dracup K, Napolitano LM, Stanford GG and Klibanski A. Serum prolactin concentrations in patients with the acquired immunodeficiency syndrome. Critical Care Med. 1990; 18:440-1.

75. Walker BD, Flexner C, Paradis TJ, Fuller TC, Hirsch MS, Schooley RT and Moss B. HIV- 1 reverse transcriptase is a target for cytotoxic T-lymphocytes in infected individuals. Science. 1988; 240:64-6.

76. Vogt MW, Durno AG, Chou TC, Coleman LA, Paradis TJ, Schooley RT, Kaplan JC and Hirsch MS. Synergistic interaction of 2',3'- dideoxycytidine (ddCyd) and recombinant interferon-alpha-A (r-IFN-alpha-A) on replication of HIV-1. J Infect Dis. 1988; 158:378-85.

77. Interferon Alpha Study Group. A randomized placebo-controlled trial of recombinant human interferon alpha 2a in patients with AIDS. J AIDS. 1988; 1:111-8.

78. D'Amico DJ, Skolnik PR, Kosloff BR, Pinkston P, Hirsch MS and Schooley RT. Resolution of cytomegalovirus retinitis with zidovudine therapy. Case Report. Arch Opthalmol. 1988; 106:1168-9.

79. Jones JF, Williams M, Schooley RT, Robinson C and Glaser R. Antibodies to Epstein-Barr Virus-Specific DNase and DNA Polymerase in the Chronic Fatigue Syndrome. Arch Intern Med. 1988; 148:1957-60.

80. de la Monte SM, Gabuzda DH, Ho DD, Brown RH Jr, Hedley-Whyte ET, Schooley RT, Hirsch MS and Bhan AK. Peripheral neuropathy in the acquired immunodeficiency syndrome. Annals of Neurology. 1988; 23:485-92.

81. Murray HW, DePamphilis J, Schooley RT and Hirsch MS. Circulating interferon-gamma in AIDS patients treated with interleukin-2 [letter]. N Engl J Med. 1988; 318:1538-9.

15

82. Merigan TC, Skowron G, Bozzette S, Richman D, Uttamchandani R, Fischl M, Schooley RT, Hirsch MS, Soo W, Pettinelli C, Schaumburg H and the ddC Study Group of the AIDS Clinical Trials Group. Circulating p24 antigen levels and responses to Dideoxycytidine in human immunodeficiency virus (HIV) infections. A Phase I-II Study. Ann Intern Med. 1989; 110:189-94.

83. Johnson VA, Barlow MA, Chou TC, Fisher RA, Walker BD, Hirsch MS and Schooley RT. Synergistic inhibition of human immunodeficiency virus type I (HIV-1) replication in vitro by recombinant soluble CD4 and 3'-azido-3'-deoxythymidine. J Inf Dis. 1989; 159:837-44.

84. Chao BH, Costopoulos DS, Curiel T, Bertonis JM, Chisholm P, Williams C, Schooley RT, Rosa JJ, Fisher RA and Maraganore JM. A 113 -amino acid fragment of CD4 produced in Escherichia coli blocks human immunodeficiency virus-induced cell fusion. J Biol Chem. 1989; 264:5812-7.

85. Walker BD, Flexner C, Birch-Limberger K, Fisher L, Paradis TJ, Aldovini A, Young R, Moss B and Schooley RT. Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with HIV-1. Proc Natl Acad Sci, USA. 1989; 86:9514-8.

86. Schooley RT, Merigan TC, Gaut P, Hirsch MS, Holodniy M, Flynn T, Liu S, Byington RE, Henochowicz S, Gubish E. A Phase I/II escalating dose trial of recombinant soluble CD4 therapy in patients with AIDS or AIDS Related Complex. Ann Intern Med. 1990; 112:247-253.

87. Surman OS, Flynn T, Schooley RT, Baer L, Parker S, Hirsch MS and Davis LG. A double-blind, placebo-controlled study of oral acyclovir in postherpetic neuralgia. Psychosomatics. 1990; 31:287-92.

88. Goldfeld AE, Birch-Limberger K, Schooley RT and Walker BD. HIV- 1 infection does not induce tumor necrosis factor-alpha or interferon-beta gene transcription. JAIDS. 1991; 4:41-7.

89. van der Horst C, Joncas J, Ahronheim G, Gustafson N, Stein G, Gurwith M, Fleisher G, Sullivan J, Sixbey J, Roland S, Fryer J, Champney K, Schooley R, Sumaya C and Pagano J. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. J Infect Dis. 1991; 164:788-92.

90. Conway BD, Tomford WW, Mankin HJ, Hirsch MS and Schooley RT. Radiosensitivity of HIV-1: Potential application to sterilization of bone allografts. AIDS. 1991; 5:608-9.

91. Chen YM, Zhang XQ, Dahl CE, Samuel KP, Schooley RT, Essex M and Papas TS. Delineation of type-specific regions on the envelope glycoproteins of human T-cell leukemia viruses. J Immunol. 1991; 147:2368-76.

92. Zhang XQ, Yang L, Ho DD, Kuritzkes DR, Chen IS, Ching WT, Chen YM and Schooley RT. Human T-lymphotropic virus types I- and II-specific antibody-dependent cellular cytotoxicity: strain specificity and epitope mapping. J Infect Dis. 1992; 165:805-12.

16

93. Leff JA, Oppegard MA, Curiel TJ, Brown KS, Schooley RT and Repine JE. Progressive increases in serum catalase activity in advancing human immunodeficiency virus infection. Free Radical Biol and Med. 1992; 13:143 -9.

94. Turner S, Tizard R, DeMarinis J, Pepinsky RB, Zullo J, Schooley RT and Fisher R. Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp 120. Proc Nat Acad Sci. 1992; 89:1335-9.

95. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, Schooley RT, Isaacson D, Doran M, Delvecchio A, Deirnonico FL, Auchincloss H Jr and Rubin RH. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody serpositive renal transplant recipient treated with OKT3. Transplantation. 1992; 53:68-72.

96. Conway BD, Baskar P, Bechtel LJ, Kaplan JC, Hirsch MS, Schooley RT and Pincus SH. Eosinophils as host cells for HIV-1. Arch Virol. 1992; 127:373-7.

97. Curiel TJ, Wong JT, Gorczxya PF, Schooley RT and Walker BD. CD4+ humanimmunodeficiency virus type 1 (HIV-1) envelope-specific cytotoxic T lymphocytes derived from the peripheral blood of an HIV-1-infected individual. AIDS Res Hum Retroviruses. 1993; 9:61-8.

98. Choi S, Lagakos SW, Schooley RT and Volberding PA. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV inaction taking zidovudine. Ann Intern Med. 1993; 118:674-80.

99. McFarland EJ, Curiel TJ, Schoen DJ, Rosandich ME, Schooley RT and Kuritzkes DR. Cytotoxic T lymphocyte lines specific for human immunodeficiency virus type I gag and reverse transcriptase derived from a vertically infected child. J Infect Dis. 1993; 167:719-23.

100. Ho DD, Cao Y, Zhu T, Farthing C, Wang N, Gu G, Schooley RT and Daar ES.Idiopathic CD4+ T-lymphopenia - immunodeficiency without evidence of HIV infection. New Engl J Med. 1993; 328:380-5.

101. Hibberd PL, Surman OS, Bass M, Tolkoff-Rubin NE, Cosimi AB, Schooley RT, Doran M, Delvecchio A, Rosal M and Rubin R. Psychiatric disease and cytomegaloviras viremia in renal transplant recipients. Phychosomatics. 1995; 36:561-3.

102. Larder BA, Kohli A, Bloor S, Kemp SD, Harrigan PR, Schooley RT, Lange JM, Pennington KN, St. Clair MH and the protocol 34, 225-02 Collaborative Group. Human immunodeficiency virus type I drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxycytidine combination therapy. J Virol. 1996; 70:5922-9.

103. Schooley RT, Campbell TB, Kuritzkes DR, Blaschke T, Stein DS, Rosandich ME, Phair J, Pottage JC, Messari FA, Collier A, Kahn J and the ACTG 184 Protocol Team. A Phase I

17

Study of Combination Therapy with L-697, 661 and Zidovudine. J AIDS & Human Retrovirology. 1996; 12:363-70.

104. Schooley RT, Raniirez-Ronda C, Lange JMA, Cooper DA, Lavelle J, Lefkowitz L, Moore M, Larder BA, St. Clair M, Mulder JW, McKinnis R, Pennington KN, Harrigan PR, Kinghorn I, Steel H, Rooney JF and the Wellcome Resistance Study Collaborative Group. Virologic and Immunologic Benefits of Initial Combination Therapy with Zidovudine and Zalcitabine or Didanosine Compared to Zidovudine Monotherapy. J Infect Dis. 1996; 173:1354-66.

105. Connick E, Marr DG, Zhang XQ, Clark SJ, Saag MS, Schooley RT and Curiel TJ.HIV-specific cellular and humoral immune responses in primary HIV infection. AIDS Res Hum Retroviruses. 1996; 12:1129-40.

106. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS and Merigan TC. A trial comparing nucleoside monotherapy with combination therapy in HIV- infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Team. N Engl J Med. 1996; 335:1081-90.

107. Uherova P, Connick E, MaWhinney S, Schlichtemeier R, Schooley RT and Kuritzkes DR. In vitro effect of interleukin-12 on antigen-specific lymphocyte proliferative responses from persons infected with human immunodeficiency virus type 1. J Infect Dis. 1996; 174:483-9.

108. Zhang X, Fitzpatrick L, Badaro R and Schooley RT. Seroprevalence of HHV-8 in Patients with and at Risk for Kaposi's Sarcoma in the US and Brazil:. J Acquired Immune Deficiency Syndromes & Human Retrovirology. 1997; 14:A22.

109. Hughes MD, Daniels MJ, Fischl MA, Soyeon K and Schooley RT. CD4 Cell Count as aSurrogate Endpoint in HIV Clinical Trials: A Meta-Analysis of Studies of the AIDS Clinical Trials Group. AIDS. 1998; 12:1823-32.

110. McFarland EJ, Harding PA, MaWhinney S, Schooley RT and Kuritzkes DR. In vitro effects of interleukin-12 on human immunodeficiency virus type 1 (HIV-1) specific cytotoxic T-lymphocyte lines from HIV-1 infected children. J Immun. 1998; 161:513-9.

111. Mitsuyasu RT, Skolnik PR, Cohen SR, Conway B, Gill MJ, Jensen PC, Pulvirenti JJ, SlaterLN, Schooley RT, Thompson MA, Torres RA, Tsoukas CM, Salgo M, Delora P, Shear M, Beattie D, Nestle J, Wolfarth C, Craig C and Duff FP. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. AIDS. 1998; 12:F103-9.

112. Zhang XQ, Fitzpatrick L, Campbell TB, Badaro R, Schechter M, Melo MD, Brites C, Pedral-Sampaio D and Schooley RT. Comparison of the prevalence of antibodies to human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) in Brazil and Colorado. J Infect Dis. 1998; 178:1488-91.

18

113. Saag MS, Sonnerborg A, Torres RG, Lancaster D, Gazzard BG, Schooley RT, Romero C,Kelleher D, Spreen W, LaFon S and the Abacavir Phase 2 Clinical Team. Antiretroviral Effect and Safety of Abacavir Alone and in Combination with Zidovudine in HIV-Infected Adults. AIDS. 1998; 12:F203-9.

114. Fitzpatrick LK, Gwanzura L, Zhang X, Mason P, Chikuni O, Schooley R and Katzenstein D. Epidemiologic Studies of Human Herpes Virus-8 in Zimbabwe. J Acquired Immune Deficiency Syndromes & Human Retrovirology. 1998; 17:A14.

115. Zhang XQ, Schooley, RT and Gerber JG. The Effect of Increasing –Acid Glycoprotein Concentration on the Antiviral Efficacy of Human Immunodeficiency Virus Protease Inhibitors. J Infect Dis. 1999; 180:1833-7.

116. Haubrich R, Thompson M, Schooley RT, Lang W, Stein A, Sereni D, van der Ende ME, Antunes F, Richman D, Pagano G, Kahl L, Fetter A, Brown DJ, Clumeck N, and the Amprenavir PROAB2002 Study Team. A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. AIDS. 1999; 13:2411-20.

117. Campbell TB, Fitzpatrick L, MaWhinney S, Zhang X and Schooley RT. Human Herpesvirus 8 (Kaposi's Sarcoma-Associated Herpesvirus) Infection in Men Receiving Treatment for HIV-1 Infection. J Acquired Immune Deficiency Syndromes & Human Retrovirology. 1999; 22:333.

118. Schooley RT, Mladenovic J, Sevin A, et al. Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease. J Infect Dis 2000; 181:148-157.

119. Schooley RT. Spino C. Kuritzkes D. Walker BD. Valentine FA. Hirsch MS. Cooney E. Friedland G. Kundu S. Merigan TC Jr. McElrath MJ. Collier A. Plaeger S. Mitsuyasu R. Kahn J. Haslett P. Uherova P. deGruttola V. Chiu S. Zhang B. Jones G. Bell D. Ketter N. Twadell T. Chernoff D. Rosandich M. Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214. J Infect Dis. 2000; 182:1357-64.

120. Fahey JL. Aziz N. Spritzler J. Plaeger S. Nishanian P. Lathey JL. Seigel J. Landay AL. Kilarui R. Schmitz JL. White C. Wara DW. Akridge R. Cutili J. Douglas SD. Reuben J. Shearer WT. Nokta M. Polland R. Schooley R. Asthana D. Mizrachi Y. Waxdal M. Need for an external proficiency testing program for cytokines, chemokines, and plasma markers of immune activation. Clin & Diag Lab Immun. 2000; 7:540-8.

121. Campbell TB. Sevin A. Coombs RW. Peterson GC. Rosandich M. Kuritzkes DR. Mladenovic J. Landay A. Wong R. Ambruso D. Miles S. Pomerantz RJ. Schooley RT. Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. Adult AIDS Clinical Trials Group 285 Study Team. Blood. 2000; 95:48-55.

19

122. Campbell TB, Borok M, Gwanzura L, MaWhinney S, White IE, Ndemera B, Gudza I, Fitzpatrick L and Schooley RT. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage. AIDS. 2000; 14:2109-16.

123. Schooley RT. Clumeck N. Haubrich R. Thompson M. Danner SA. van Der Ende ME. Sereni D. Antunes F. Blake D. Myers RE. Tisdale M. Millard J. Mustafa N. Nacci P. A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience. Antiviral Therapy. 2001; 6:89-96.

124. Connick E. Schlichtemeier RL. Purner MB. Schneider KM. Anderson DM. MaWhinney S. Campbell TB. Kuritzkes DR. Douglas JM Jr. Judson FN. Schooley RT. Relationship between human immunodeficiency virus type 1 (HIV-1)-specific memory cytotoxic T lymphocytes and virus load after recent HIV-1 seroconversion. J Infect Dis. 2001; 184:1465-9.

125. Schacker T. Little S. Connick E. Gebhard K. Zhang ZQ. Krieger J. Pryor J. Havlir D. Wong JK. Schooley RT. Richman D. Corey L. Haase AT. Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. J Infect Dis. 2001; 183:555-62.

126. Burman WJ, Reves RR, Cohn DL and Schooley RT. Breaking the Camel's Back: Multicenter Clinical Trials and Local Institutional Review Boards. Ann Intern Med. 2001; 134:152-7.

127. Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, Chen SS, Miller MD, Isaacson E and Cheng AK for the Study 902 Team. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. 2002; 16:1257-63.

128. Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT and Miller MD. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS. 2002; 16:1227-35.

129. Garcia R, Schooley RT, Badaro R. An adherence trilogy is essential for long-term HAART success. Braz J Infect Dis. 2003;7:307-14.

130. Campbell TB, Rapaport E, Schooley RT and Kuritzkes DR. Increased replication of HIV-1 minor variants during hematopoietic stem-cell mobilization with filgrastim. J Infect Dis 2004; 190: 257-66.

131. Neid JM, Schooley RT and Campbell TB. Stimulation of Kaposi’s Sarcoma-associated Herpesvirus Viremia During Hematopoietic Stem Cell Mobilization with Filgrastim. Blood. 2004. 190: 257-66.

132. Schooley, RT. HIV and hepatitis C virus coinfection: bad bedfellows. Top HIV Med. 2005;13:112-6

20

133. Zhang X-Q, Sorensen M, Fung M and Schooley RT. Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX355) and enfuvirtide. Antimicrobial Agents and Chemother. 2006; 50: 2231-3.

134. Garcia R, Badaró R, Netto EM, Silva M, Amorin FS, Ramos A, Vaida F, Brites C and Schooley RT Cross-sectional study to Evaluate Factors Associated with Adherence To Antiretroviral Therapy by Brazilian HIV Infected Patients. AIDS and Related Human Retroviruses. 2006; 22: 1248-52.

135. Frey G, Rits-Volloch S, Zhang X-Q , Schooley RT, Chen B, Harrison SC. Small molecules that bind the inner core of gp41. Proc Nat Acad Sci USA 2006;103:13938-43.

136. Sailer CA, Pott GB, Dinarello CA, MaWhinney S, Forster JE, Larson-Duran JK, Landay A, Al-Harthi L, Schooley RT, Benson CA, Judson FN, Thompson M, Palella FJ and Shapiro L. Whole Blood Interleukin-18 Concentration During Early HIV-1 Infection is Associated with Reduced CXCR4 Coreceptor Expression and Interferon (IFN)γ Levels. J Infect Dis. 2007; 195: 734-8.

137. Wyles DW, Kaihara KA, Vaida F and Schooley RT. Synergy of small molecular inhibitors of HCV replication directed at multiple viral targets. J Virol. 2007; 81:3005-8.

138. Al-Harthi L, MaWhinney S, Connick E, Schooley RT, Forster JE, Benson CA, Thompson M, Judson F, Palella F and Landay A. Immunophenotypic alterations in acute and early HIV infection. Clin Immunol 2007; 125: 299-308.

139. Grünberger C, Wyles DL, Kaihara KA, and Schooley RT. Three-Drug synergistic interactions of small molecular inhibitors of Hepatitis C virus (HCV) replication. J Infect Dis 2008. 197: 42-5.

140. Wyles DL, Kaihara KA and Schooley RT. Synergy of an HCV NS4A Antagonist in Combination with HCV protease and polymerase inhibitors. Antimicrobial Agents Chemother, 2008, 52:1862-4.

141. Wilson CC, Newman MJ, Livingston BD, Forster JF, MaWhinney S, Scott J, Schooley RT and Benson CA, Clinical Phase 1 Safety and Immunogenicity Testing of an Epitope-based DNA Vaccine in HIV-1-infected Subjects Receiving Highly Active Antiretroviral Therapy (HAART) Clin Vaccine Immunol, 2008 6:986-94.

142. Mehta SR, Huang R, Yang M, Zhang X-Q, Kolli B, Chang K-P, Hoffman RM, Goto Y, Badaro B and Schooley RT. Real time GFP imaging in a murine leishmaniasis model: a new tool for leishmania vaccine and drug discovery. Clin Vaccine Immunol. 12: 1764-70; 2008.

143. Wyles DW, Kaihara KA, Korba BE, Schooley RT, Beadle JR and Hostetler KY. ODE-(S)-HPMP is a potent and selective inhibitor of Hepatitis C Virus replication in Genotype 1A, 1B and 2A replicons. Antimicrobial Agents Chemother. 2009;53:2660-2.

21

144. Kumarasamy N, Madhavan V, Venkatesh KK, Saravanan S, Kantor R, Balakrishnan P, Devaleenol B, Poongulali S, Yepthomi T, Solomon S, Mayer K, Benson C and Schooley R. High frequency of clinically significant mutations following first-line generic HAART failure: Implications for second line options in resource-limited settings. Clin Infect Dis. 2009;49:306-9.

145. Lu Q, Zhang X-Q, Pond SLK, Reed SL, Schooley RT, Liu Y-T, Detection in 2009 of the Swine-Origin Influenza A (H1N1) Virus by a Subtyping Microarray. J Clin Micro 2009; 47: 3060-1.

146. Asmuth DM, Murphy RL, Rosenkranz SL, Lertora JJ, Kottilil S, Cramer Y, Chan ES, Schooley RT, Rinaldo CR, Thielman N, Li XD, Wahl SM, Shore J, Janik J, Lempicki RA, Simpson Y, Pollard RB; AIDS Clinical Trials Group A5192 Team. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J Infect Dis. 2010; 201:1686-96.

147. Chen C-H, Zhang X-Q, Lo C-W, Liu Y-T, Gallo RL, Hsien M-F, Schooley RT and Chun-Ming Huang. The essentiality of alpha-2-macroglobulin in human salivary innate immunity against new H1N1 swine origin influenza A virus. Proteomics. 2010; 10:2396-401.

148. Rodwell TC, Robertson A, Vera A, Anderson C; Lozada R, Aguirre N, Chait L, Schooley RT, Zhang, X-Q, Strathdee S. Rapid Response Survey of Influenza A (H1N1) in Marginalized Populations in Tijuana, Mexico: Lessons Learned. Emerging Infect Dis, 2010;16:1292-5.

149. Schooley RT, Spritzler J, Wang H, Lederman MM, Havlir D, Kuritzkes DR, Pollard RB,

Battaglia C, Robertson M, Mehrotra D, Casimiro D, Cox K, Schock B and the ACTG 5197 Study Team ACTG 5197: A Placebo Controlled Trial of Immunization of HIV-1 Infected Persons with a Replication Deficient Ad5 Vaccine Expressing the HIV-1 Core Protein J Infect Dis, 2010;202:705-16.

150. Borok M, Fiorillo S, Gudza I, Putnam B,, Ndemera B, White IE, Gwanzura L, Schooley RT, Campbell TB. Evaluation of Plasma Human Herpesvirus 8 DNA as a Marker of Clinical Outcomes During Antiretroviral Therapy of AIDS-related Kaposi's Sarcoma in Zimbabwe. Clin Infect Dis. 2010;51:342-9. PMID: 20572760

151. Lockman S, Hughes M, McIntyre J, Zheng Y, Chipato T, Conradie F, Sawe F, Asmelash A, Hosseinipour M, Mohapi L, Stringer E, Mngqibisa R, Siika A, Atwine D, Hakim J, Shaffer D, Kanyama C, Wools-Kaloustian K, Salata R, Hogg E, Alston-Smith B, Walawander A, Purcelle-Smith E, Eshleman S, Rooney J, Rahim S, Mellors J, Schooley R, Currier J. A Trial of Two Antiretroviral Therapies in Women with and without Prior Nevirapine Use. New Engl J Med, 363:1499-509.

152. Mehta SR, Zhang X-Q, Badaro R, Spina C, Day J, Chang K-P and Schooley RT. Flow Cytometric Screening for Anti-Leishmanials in a Human Macrophage Cell Line. Experimental Parasitology, 2010; 126: 617-20.

22

153. Thompson MA (Panel Chair), Aberg JA, Cahn P, Montaner JSG, Rizzardini G, Telenti A, Gatell JM, Günthard HF, Hammer SM, Hirsch MS; Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT (Panel Vice-Chair). Antiretroviral Treatment of Adult HIV Infection: 2010 Recommendations of the International AIDS Society-USA Panel. JAMA. 2010; 304; 321 – 33.

154. Meditz AL, MaWhinney S, Allshouse A, Feser W, Markowitz M, Little S, Hecht R, Daar ES, Collier AC, Margolick J, Kilby JM, Routy J-M, Conway B, Kaldor J, Levy J, Schooley R, Cooper DA, Altfeld M, Richman D, Connick E. Sex, Race, and Geographic Region Influence Clinical Outcomes Following Primary HIV-1 Infection. J Infect Dis. 2011; 140:755-60

155. Li JZ, Brumme ZL, Brumme CJ, Wang H, Spritzler J, Robertson M, Lederman MM, Mary Carrington M, Walker BD, Schooley RT, Kuritzkes DR and the AIDS Clinical Trials Group A5197 Study Team. Factors Associated with Viral Rebound in HIV-Infected Individuals Enrolled in a Therapeutic HIV-1 gag Vaccine Trial. J Infect Dis, 2011; 203:976-83.

156. Recommendations on sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: Consensus from the HCV DRAG. Sequence Analysis Working Group (SAWG) and Phenotype Analysis Working Group (PAWG). Kwong AD, Najera I, Bechtel J, Bowden S, Fitzgibbon J, Harrington P, Kempf D, Kieffer TL, Koletzki D , Kukolj G, Lim S, Pilot-Matias T, Lin K, Mani N, Mo H, O’Rear J, Otto M, Parkin N, Pawlotsky J-M, Petropoulos C, Picchio G, Ralston R, Reeves JD, Schooley RT, Seiwert S, Standring S, Stuyver L, Sullivan J, Miller V under the auspices of the Forum for Collaborative HIV Research and on behalf of the HCV Drug Development Advisory Group (HCV DRAG). Gastroenterology. 2011; 140:755-60

157. Holmes EC, Ghedin E, Halpin RA, Stockwell TB, Zhang, X-Q, Fleming R, Davey R, Benson CA, Mehta SR, Taplitz RA, Liu Y-T, Brouwer KC, Wentworth DE, Lin X, INSIGHT FLU002 Study Group and Schooley RT. Extensive Geographical Mixing of Human H1N1/09 Influenza A Virus in a Single University Community. J Virol, 2011; 14; 6923-9.

158. Valiaeva N, Wyles DL, Schooley RT, Hwu JB, James R. Beadle JR Prichard MN, Hostetler KY. Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: Inhibitors of hepatitis C virus and HIV-1 replication. Bioorganic and Med Chem, 2011: 19; 4616-25.

159. Rodrigues MAZ, Grassi MFR, Mehta SR, Zhang X-Q, Gois LL, Schooley RT and Badaro R. Th1/Th2 Cytokine Profile in HIV and Leishmania Co-infected patients in Brazil. Clin Vaccine Immunol 2011.49:3584-90.

160. Lochhead MJ, Todorof K, Delaney M, Ives JT, Greef C, Moll K, Rowley K, Vogel K, Myatt C, Zhang XQ, Logan C, Benson C, Reed S, Schooley RT. Rapid multiplexed immunoassay for simultaneous serodiagnosis of HIV-1 and coinfections. J Clin Microbiol. 2011;49:3584-90.

161. Zhu H, Wong-Staal F, Lee H, Syder A, McKelvy J, Schooley RT, Wyles DL.

23

Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. J Infect Dis. 2012; 205:656-62.

162. Manion M, Rodriguez B, Medvik K, Hardy G, Harding CV, Schooley RT, Pollard R, Asmuth D, Murphy R, Barker E, Brady KE, Landay A, Funderburg N, Sieg SF, Lederman MM.Interferon-alpha administration enhances CD8+ T cell activation in HIV infection.PLoS One. 2012;7:e30306.

163. Lorenzana SB, Hughes MD, Grinsztejn B, Collier AC, Luz PM, Freedberg KA, Wood R, Levison JH, Mugyenyi PN, Salata R, Wallis CL, Weinstein MC, Schooley RT, Walensky RP. Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial. AIDS. 2012;26:1083-1093.

164. Mistro S, Maciel Ide M, de Menezes RG, Maia ZP, Schooley RT, Badaró R. Does Lipid Emulsion Reduce Amphotericin B Nephrotoxicity? A Systematic Review and Meta-analysis. Clin Infect Dis. 2012;54:1774-7.

165. Li JZ, Brumme CJ, Lederman MM, Brumme ZL, Wang H, Spritzler J, Carrington M, Medvik K, Walker BD, Schooley RT, Kuritzkes DR; AIDS Clinical Trials Group A5197 Study Team. Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial. PLoS One. 2012; 7, e34134.

166. Orlov M, Vaida F, Finney OC, Smith DM, Talley AK, Wang R, Kappe SH, Deng Q, Schooley RT *, Duffy PE. P. falciparum Enhances HIV Replication in PBMCs Isolated from Humans Undergoing an Experimental Malaria Challenge PLoS One, 2012; 7: e39000. doi:10.1371 * corresponding author.

167. Saravanan S, Madhavan V, Kantor R, Sivamalar S, Giomathi S, Solomon SS, Kumarasamy N, Smith DM, Schooley RT, Solomon S, Balakrishnan P. Unusual Insertion and Deletion at Codon 67 and 69 of HIV-1 Subtype C Reverse Transcriptase Among First-Line Highly Active Antiretroviral Treatment Failing South Indian Patients: Association with Other Resistance Mutations. AIDS Res Hum Retroviruses, 2012;28:1763-5. doi: 10.1089/AID.2011.0331. Epub 2012 May 21..

168. Lockman S, Hughes M, Sawe F, Zheng Y, McIntyre J, Chipato T, Asmelash A, Rassool M, Kimaiyo S, Shaffer D, Hosseinipour M, Mohapi L, Ssali F, Chibowa M, Amod F, Halvas E, Hogg E, Alston-Smith B, Smith L, Schooley R, Mellors J, Currier J, the OCTANE (Optimal Combination Therapy After Nevirapine Exposure) ACTG A5208/OCTANE StudyTeam. Nevirapine- Versus Lopinavir/Ritonavir-Based Initial Therapy for HIV-1 Infection among Women in Africa: A Randomized Trial. PLoS Medicine, 2012; 9: e1001236.

169. Li JZ, Brumme CJ, Lederman MM, Brumme ZL, Wang H, Spritzler J, Carrington M, Medvik K, Walker BD, Schooley RT, Kuritzkes DR; AIDS Clinical Trials Group A5197 Study Team. Characteristics and outcomes of initial virologic suppressors during analytic

24

treatment interruption in a therapeutic HIV-1 gag vaccine trial. PLoS One. 2012;7:e34134. doi: 10.1371/journal.pone.0034134. Epub 2012 Mar 30.

170. Noormahomed EV, Orlov M, do Rosario V, Petersen BW, Guthrie C, Badaro R, Schooley RT. A cross-sectional study of sub-clinical Plasmodium falciparum infection in HIV-1 infected and uninfected populations in Mozambique, South-Eastern Africa. Malar J. 2012;11:252. doi: 10.1186/1475-2875-11-252. PMID: 22853699

171. Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C, Grinsztejn B, Hosseinipour MC, Kumwenda J, Lalloo U, Riviere C, Sanchez J, Melo M, Supparatpinyo K, Tripathy S, Martinez AI, Nair A, Walawander A, Moran L, Chen Y, Snowden W, Rooney JF, Uy J, Schooley RT, De Gruttola V, Hakim JG; PEARLS study team of the ACTG. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med. 2012;9(8):e1001290. Epub 2012 Aug 14. PMID: 22936892

172. Saravanan S, Madhavan V, Balakrishnan P, Smith DM, Solomon SS, Sivamalar S, Poongulali S, Kumarasamy N, Schooley RT, Solomon S, Kantor R. Darunavir Is a Good Third-Line Antiretroviral Agent for HIV Type 1-Infected Patients Failing Second-Line Protease Inhibitor-Based Regimens in South India. AIDS Res Hum Retroviruses. 2013;29:630-2. doi: 10.1089/AID.2011.0334. Epub 2012 Dec 7. PMID:23045961

173. Logan C, Givens M, Ives JT, Delaney M, Lochhead MJ, Schooley RT, Benson CA. Performance evaluation of the MBio Diagnostics point-of-care CD4 counter. J Immunol Methods. 2013;387:107-13. doi: 10.1016/j.jim.2012.10.002. Epub 2012 Oct 11. PMID: 23063690.

II. Invited Articles, Book Chapters, Review Articles, Edited Books, Editorials and Monographs.

1. Schooley RT and Dolin R. Epstein-Barr Virus (Infectious Mononucleosis) In: Principles and Practice of Infectious Diseases, John Wiley and Sons, New York. 1979; 1324-41.

2. Schooley RT and Hirsch MS. Epstein-Barr Virus: Current Concepts. Infect Disease Practice.1980; 3:1-7.

3. Schooley RT, Parrillo JE, Wolff SM and Fauci AS. Management of the idiopathic hypereosinophilic syndrome. In: The Eosinophil. Mahmood AAF, and Austin KF, Eds, Grune and Stratton. 1980; 323-43.

4. Hirsch MS, Cheeseman SH, Rubin RH, Schooley RT, Henle W, Lennette ET, Andrews C, Shah KV and Cantell K. Prophylactic interferon-alpha (IFN-) in renal transplant recipients. In: The Biology of the Interferon System, DeMaeyer E, Galasso G and Schellekens H, eds. Elsevier/North-Holland. Biomedical Press. 1981.

5. Schooley RT. Infectious Mononucleosis: Etiology. In: Infectious Mononucleosis. Schlossberg D, ed. Praeger Scientific. New York, 1982; 1-13.

25

6. Southwick FS and Schooley RT. Infectious Diseases. In: Blackshear PS, ed. Key References in Internal Medicine. New York: Churchill Livingstone, 1982.

7. Hirsch MS, Schooley RT, Rubin RH, Tolkoff-Rubin NE and Cantell K. Interferon in renal transplant recipients. In: Interferons UCLA Symposia on Molecular and Cellular Biology. Merigan TC and Friedman RM. 1982; 25:421-5.

8. Schooley RT. Susceptibility to Acquired Immune Deficiency Syndrome (AIDS): Clinical Practice Update. Volume 2, Number 4, February 21, 1983.

9. Hirsch MS and Schooley RT. Drug Therapy. Treatment of herpesvirus infections. N Engl J Med. 1983; 309:963-70, 1034-9.

10. Schooley RT: How to manage infectious mononucleosis. Drug Therapy. December, 1983; 13:68-77.

11. Hirsch MS, Schooley RT, Ho DD and Kaplan JC. Possible Viral Interactions in the Acquired Immunodeficiency Syndrome (AIDS). Rev Infect Dis. 1984; 6:726-31.

12. Schooley RT, Hirsch MS, Rubin RH and Cantell K. The role of interferons in viral infections in immune compromised patients. In: Transplantation and Blood Transfusion. C. Th. Smit Sibinga, P. C. Das, G. Opelz. 1984; 83-9.

13. Schooley RT and Dolin R. Epstein-Barr Virus (Infectious Mononucleosis). In: Principles and Practice of Infectious Diseases, John Wiley and Sons, New York, Second Edition. 1984; 971-82.

14. Hirsch MS and Schooley RT. Interferon trials in immunocompromised patients. In: The Biology of the Interferon System. Kirchner H and Schellekens H. ed. Amsterdam. Elsevier, 1985.

15. Blumberg RS and Schooley RT. Lymphocyte markers and infectious diseases. Seminars in Hematology. 1985; 22:81-114.

16. Vogt MW, Addison R, Schooley RT and Hirsch MS. Are apheresis personnel at risk for AIDS Plasma Therapy & Transfusion Technology. 1986; 7:515-20.

17. Schooley RT. Epstein Barr virus infections, including mononucleosis in Harrison's Textbook of Internal Medicine. 11th Edition, McGraw-Hill, New York. 1987; 699-703.

18. Schooley RT. AIDS In: Primary Care Medicine. 2nd Edition, Lippincott, Philadelphia, AM Gorell, LA May, AG Mulley (Ed). 1987; 637-41.

19. Vogt MW and Schooley RT. An overview of antiviral therapy of HTLV-III/LAV infection. Noyes Publications. 1987.

26

20. Schooley RT. Encephalitis. In: Neurological and Neurosurgical Intensive Care. A. H. Ropper and S. F. Kennedy, Aspen Publication, Rockville, Maryland, Second Edition. 1988; 289-307.

21. Schooley RT. Prophylactic and Therapeutic perspective in viral infections In: Infections in Transplant Patients. Georg Thieme Verlag Stuttgart, 1987; 205-24.

22. Schooley RT, Blumberg RS, Vogt M, Hartshorn K and Hirsch MS. Therapeutic perspectives in human immunodeficiency virus infection. J Exp Pathol. 1987; 3:661-80.

23. Vogt M, Schooley RT and Hirsch MS. Chemotherapie und immunoprophylaxe der HIV-infektion. Schweizerische Rndschau fur Medizin Praxis. 1986; 75:1471-5.

24. Schooley RT. Perspectives for lymphokine therapy: from genetic engineering to immunologic engineering. 1987, C. Th. Smit Sibinga, P.D. Das, C. P. Engelfriet, Editors. Nijhoff Publishing. 131-42.

25. Pomerantz RJ and Schooley RT. Therapy of Human Immunodeficiency Virus Infections. Clinics in Laboratory Medicine. 1987; 7:793-813.

26. Schooley RT. Interferon Alpha in the Therapy of Patients with HW Infections. In: HIV and Other Highly Pathogenic Viruses, Academic Press Inc. Roberts A. Smith, Eds. 1987; 113-24.

27. Sibinga CT, de Vries B, McShine RL, Das PC and Schooley RT. HIV antibody screening in a low-risk population (blood donors) [letter]. Transfusion. 1987; 27:215-6.

28. Schooley RT. The Quest for an AIDS Vaccine. N Engl J Public Policy. 1988; 135-44.

29. Schooley RT. AIDS: Clinical Aspects and Biologic Therapies. Immunology and Allergy Clinics. 1988; 93-109.

30. Schooley RT. Chronic Fatique Syndrome: A Manifestation of Epstein-Barr Virus Infection? In: Current Clinical Topics in Infectious Diseases. JS Remington and MN Swartz, McGraw-Hill Book Co. 1988; 9:126-46.

31. Schooley RT. Morbidity in Compromised Patients Due to Viruses Other Than Herpes Group and Hepatitis Viruses. In: Clinical Approach to Infection in the Compromised Host. 2nd Edition. RH Rubin and LS Young. Plenum Book Company, New York and London. 1988.

32. Schooley RT. Waltzing HIV-tilda (editorial). Arch Intern Med. 1988; 148(4):778.

33. Pomerantz RJ and Schooley RT. Therapy of human immunodeficiency virus infections. Clin Lab Med. 1987; 7(4):793-813.

34. Hirsch MS and Schooley RT. Resistance to antiviral drugs: the end of innocence (editorial). N Engl J Med. 1989; 320(5):313-4.

27

35. Schooley RT. Epstein-Barr virus. Current Opinion in Infectious Diseases. 1989; 2:267-71.

36. Schooley RT and Dolin R. Epstein-Barr Virus (Infectious Mononucleosis). In: Principles and Practice of Infectious Diseases, John Wiley and Sons, New York, Third Edition. 1989; 1172-85.

37. Johnson RP and Schooley RT. Update on antiretroviral agents other than zidovudine. AIDS. 1989; 3:S 145-51.

38. Schooley RT. Infectious Mononucleosis. In: Merck Manual of Diagnosis and Theapy. Merck Sharp & Dohme Research Laboratories, Rahway, NJ. 15th Edition.

39. Schooley RT. Cytomegalovirus in the setting of infection with human immunodeficiency virus. Rev Infect Dis. 1990; 12:S811-9.

40. Schooley RT, Strongin W and Hawley P. Methodological issues in AIDS clinical trials. Discussion. Design of clinical trials-end points. J Acquir Immune Defic Syndr. 1990; 3:S72-6.

41. Schooley RT. Pneumonia Due to Herpesviruses. In: Respiratory Disease in the Immunosuppressed Host. J Shelhamer, et al. J. B. Lippincott Company, Philadelphia. 1991; 386-97.

42. Schooley RT. Challenges in the clinical development of antiretroviral drugs. Antiviral Research. 1992; 17:305-10.

43. Fahey JL and Schooley RT. Status of immune-based therapies in HIV infection and AIDS. Clin Exp Immunol. 1992; 88:1-5.

44. Schooley RT. Encephalitis. In: Neurological and Neurosurgical Intensive Care, Third Edition, A.H. Ropper, Raven Press, New York. 1992; 411-35.

45. Schooley RT. Herpesvirus Infection in Individuals with HIV Infection. In: AIDS: Etiology, Diagnosis, Treatment, and Prevention, Third Ed, V.T. DeVita, S. Hellman and S.A. Rosenberg, J.B. Lippincott Company, Philadelphia. 1992; 193-207.

46. Schooley RT. Antiretroviral Chemotherapy. In: AIDS and Other Manifestations of HIV Infection. G.P. Wormser, Raven Press, New York. 1992; 609-23.

47. Schooley RT. Just (Don't) Do It. J Clin Invest. 1993; 92:535.

48. Connick E and Schooley RT. HIV-1 Specific Immune Responses. In: HIV Molecular Organization, Pathogenicity and Treatment. W.J.W. Morrow and N. Haigwood. Elsevier Science Publishers, The Netherlands. 1993; 75-98.

28

49. Schooley RT. Immune Based Therapies for HIV-1 Infection. In: Textbook of AIDS Medicine. S. Broder, D.P. Bolognesi and T.C. Merigan, Jr. Williams and Wilkins, Baltimore. 1994; 713-20.

50. Schooley RT. Chronic Fatigue Syndrome. In: Principles and Practice of Infectious Diseases, John Wiley and Sons, New York, Fourth Edition, 1994.

51. Schooley RT and Dolin R. Epstein-Barr Virus (Infectious Mononucleosis). In: Principles and Practice of Infectious Diseases, John Wiley and Sons, New York, Fourth Edition, 1994.

52. Schooley RT. Correlation between viral load measurements and outcome in clinical trials of antiviral drugs. AIDS. 1995; 9:S15-9.

53. Schooley RT. HIV-1 specific cytotoxic T-cell responses. AIDS. 1995; 9:S113-6.

54. Schooley RT. Immunomodulatory effects of antiretroviral chemotherapy. J Biol Regul Homeost Agents. 1995; 9:110-3.

55. Schooley RT. Enhancing HIV-1 Specific Immunity as a Therapeutic Strategy in AIDS. Advances in Exper Med and Biol. 1996; 394:405-10.

56. Benson EM, French MA and Schooley RT. Managing HIV. Part 4: Primarytherapy. 4.2 Immune-based therapy for HIVinfection. Med J Australia. 1996; 164:297-300.

57. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG and Volberding PA. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA. 1996; 276:146-54.

58. Cotton D, Bartlett J, Schooley R, Gulick R. Therapeutic decision making in 1997.

59. Schooley RT. Check, but not checkmate. Antiviral Therapy. 1997; 2:68-9.

60. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG and Volberding PA. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA. 1997; 277:1962-9.

61. Carpenter CC, Feinberg M, Schooley RT, (23 panel members). Report of the NIH Panel to Define Principles of Therapy of HIV Infection and Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Ann lntern Med. 1998; 128:1057-1100.

62. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG and Volberding PA. Antiretroviral therapy for HIV infection in 1998. Updated recommendations of the International AIDS Society-USA panel. JAMA. 1998; 280:78-86.

29

63. Saag MS and Schooley RT. Antiretroviral chemotherapy. Curr Clin Top Infect Dis. 1998; 18:154- 79.

64. Schooley, RT. Longer-term immunologic effects and side effects of successful antiretroviral therapy. Clin Infect Dis. 1999; 29:12-8.

65. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG and Volberding PA. Antiretroviral Therapy in Adults. Updated recommendations of the International AIDS Society - USA Panel. JAMA. 2000; 283:381-90.

66. Yeni PG, Hammer SC, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S and Volberding PA. Antiretroviral Treatment for Adult HIV Infection in 2002: Updated recommendations of the International AIDS Society - USA Panel. JAMA. 2002; 288:222-35.

67. Schooley RT. Antiretroviral Chemotherapy. In: AIDS and Other Manifestations of HIV Infection. (Fourth Edition) G.P. Wormser, Raven Press, New York. 2002; 827-840.

68. Yeni PG, Hammer SC, Hirsch MS, Saag MS, Schechter M, Carpenter CCJ, Fischl MA, Gatell JM, Gazzard BG, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Schooley RT, Thompson MA, Vella S and Volberding PA. Treatment of Adult HIV Infection: 2004 Recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292: 251-65.

69. Schooley RT. Starting highly active antiretroviral therapy for HIV infection: is it WIHS to wait? Ann Intern Med. 2004;140:305-6.

70. Schooley RT. Human Retroviruses: AIDS and Other Diseases. In Mechanisms of Microbial Diseases.(Fourth Edition) Engleberg NC, DiRita V and Dermody TS, Eds. Lippincott Williams and Wilkins. 2006 pp 376-388.

71. Hammer SM, Saag, MS, Schechter, M, Montaner JSG, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CCJ, Fischl MA, Gazzard BG, Gatell JM, Hirsch, MS,. Katzenstein DA, Richman DD; Vella S, Yeni PG, Volberding, PA. Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society–USA Panel. JAMA, 2006; 296: 827-43.

72. Schooley RT. Epstein Barr Virus Infection. In Cecil’s Textbook of Internal Medicine. 2007. In press.

73. Schooley RT. Viral Load Testing in Resource Limited Settings. Clin Infect Dis. 2007; 44: 139-40.

30

74. Schooley RT and Mellors JW. No Cure Yet for HIV-1 But Therapeutic Research Presses On. J Infect Dis. 2007; 195: 770-2.

75. Smith DM and Schooley RT. Running with Scissors: Using Antiretroviral Therapy without Monitoring Viral Load. Clin Infect Dis. 2008; 46: 1598-1600.

76. Grant RM, Hamer D, Hope T, Johnston R, Lange J, Lederman MM, Lieberman J, Miller CJ, Moore JP, Mosier DE, Richman DD, Schooley RT, Springer MS, Veazey RS, Wainberg MA. Whether or Wither Microbicides. Science, 2008; 321: 532-4.

77. Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl, MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JSG, Richman DD, Yeni PG, Volberding PA. Antiretroviral Treatment of Adult HIV Infection: 2008 Recommendations of the International AIDS Society–USA Panel. JAMA, 2008; 300:555-70.

78. DeGruttola V, Little S and Schooley. Controlling the AIDS Epidemic without a Vaccine. AIDS. 2008; 22:2554-5.

79. Wilson CC and Schooley RT. Host Responses to Infections in Infectious Diseases, Third Edition. Mosby Elsevier, London. 2010. pp 30 – 44.

80. Monto A, Schooley RT, Lai JC, Sulkowski MS, Chung RT, Pawlotsky JM, McHutchison JG, Jacobson IM. Lessons From HIV Therapy Applied to Viral Hepatitis Therapy: Summary of a Workshop. Am J Gastroenterol. 2010; 105:989-1004.

81. Wyles DL and Schooley RT. Rong’s numbers: Accelerating progress in HCV therapeutic research. Sci. Transl. Med, 2010; 2, 33ps25.

82. DeGruttola V and Schooley RT. Antiretroviral Therapy as Prevention: Linking the Mainframe to Main Street. Clin Infect Dis. 2011;52(8):1050-2.

83. Schooley RT. Hepatitis C virus therapeutics: at the end of the beginning. Top Antivir Med. 2012; 20:17-9.

31

Ongoing Federal Grant Support

Title Granting AgencyAmount of

Total Award (direct costs)

Time period of contract/grant

Role, e.g. PI, co-investigator,

project leader, etc.U01 AI074521Multiplex Nucleic Acid Detection Device for the Diagnosis of Respiratory Viruses

NIAID 4,110,114 07/10/07-06/30/12

Principal Investigator

R01AI076558Orally Active Nucleoside Phosphonates for Hepatitis C Virus

NIAID 1,758,179 04/10/09-03/31/14

Principal Investigator

2T32AI007036-31Training in Infectious Diseases

NIAID $392,000 9/1/2010-8/31/2015

Principal Investigator

5 P30 AI36214 International Core for the UCSD CFAR

NIAID $1,976,249 6/01/07 – 05/31/12

Co-PI, International Core

1R24TW008908-01Universidade Eduardo Mondlane-UCSD Medical Education Partnership

NIH Fogarty Center/PEPFAR

~$2 million 9/30/2010-9/29/2015

Co-Investigator

1 UO1 AI069432San Diego AIDS Clinical Trials Unit

NIAID $956,274 12/01/06-11/30/13

Co-Investigator

2R44AI068543Low Cost Multi-PathogenLaser Diagnostic for HIV and AIDS Co-Infections

NIAID 841,216 9/1/09-8/31/12

Co-Investigator

2R44AI070052Low Cost Multi-Pathogen Laser Diagnostic for CD4+ T-Cell Counting

NIAID $748,823 9/1/09-8/31/11

Co-Investigator

32